[go: up one dir, main page]

WO2001013902A3 - Wirkstoffkombination enthaltend Clonidin und Pramipexol - Google Patents

Wirkstoffkombination enthaltend Clonidin und Pramipexol Download PDF

Info

Publication number
WO2001013902A3
WO2001013902A3 PCT/EP2000/007718 EP0007718W WO0113902A3 WO 2001013902 A3 WO2001013902 A3 WO 2001013902A3 EP 0007718 W EP0007718 W EP 0007718W WO 0113902 A3 WO0113902 A3 WO 0113902A3
Authority
WO
WIPO (PCT)
Prior art keywords
combination
active agents
pramipexol
containing clonidine
clonidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2000/007718
Other languages
English (en)
French (fr)
Other versions
WO2001013902A2 (de
Inventor
Hans-Michael Brecht
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA002376606A priority Critical patent/CA2376606A1/en
Priority to BR0013353-1A priority patent/BR0013353A/pt
Priority to AU64406/00A priority patent/AU6440600A/en
Priority to IL14774100A priority patent/IL147741A0/xx
Priority to KR1020027002149A priority patent/KR20020060163A/ko
Priority to PL00353358A priority patent/PL353358A1/xx
Priority to EP00951485A priority patent/EP1210081A2/de
Priority to MXPA02001138A priority patent/MXPA02001138A/es
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Priority to JP2001518040A priority patent/JP2003507420A/ja
Publication of WO2001013902A2 publication Critical patent/WO2001013902A2/de
Publication of WO2001013902A3 publication Critical patent/WO2001013902A3/de
Priority to NO20020793A priority patent/NO20020793D0/no
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Die vorliegende Erfindung betrifft eine Wikstoffkombination bestehend aus Clonidin und Pramipexol zur Behandlung des Restless Leg Syndroms.
PCT/EP2000/007718 1999-08-19 2000-08-09 Wirkstoffkombination enthaltend clonidin und pramipexol Ceased WO2001013902A2 (de)

Priority Applications (10)

Application Number Priority Date Filing Date Title
EP00951485A EP1210081A2 (de) 1999-08-19 2000-08-09 Wirkstoffkombination enthaltend clonidin und pramipexol
AU64406/00A AU6440600A (en) 1999-08-19 2000-08-09 Combination of active agents, said combination containing clonidine
IL14774100A IL147741A0 (en) 1999-08-19 2000-08-09 Combination of active agents, said combination containing clonidine
KR1020027002149A KR20020060163A (ko) 1999-08-19 2000-08-09 클로니딘 및 프라미펙솔을 함유하는 활성제의 배합물
PL00353358A PL353358A1 (en) 1999-08-19 2000-08-09 Combination of active agents, said combination containing clonidine and pramipexol
CA002376606A CA2376606A1 (en) 1999-08-19 2000-08-09 Active substance combination with clonidine
BR0013353-1A BR0013353A (pt) 1999-08-19 2000-08-09 Combinação de substância ativa com clonidina
MXPA02001138A MXPA02001138A (es) 1999-08-19 2000-08-09 Combinacion de sustancias activas con clonidina.
JP2001518040A JP2003507420A (ja) 1999-08-19 2000-08-09 作用物質の組成物、クロニジンを含む前記組成物
NO20020793A NO20020793D0 (no) 1999-08-19 2002-02-18 Virkestoffkombinasjon med clonidin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19938825A DE19938825A1 (de) 1999-08-19 1999-08-19 Wirkstoffkombination mit Clonidin
DE19938825.3 1999-08-19

Publications (2)

Publication Number Publication Date
WO2001013902A2 WO2001013902A2 (de) 2001-03-01
WO2001013902A3 true WO2001013902A3 (de) 2001-08-23

Family

ID=7918574

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/007718 Ceased WO2001013902A2 (de) 1999-08-19 2000-08-09 Wirkstoffkombination enthaltend clonidin und pramipexol

Country Status (19)

Country Link
US (1) US20020010201A1 (de)
EP (1) EP1210081A2 (de)
JP (1) JP2003507420A (de)
KR (1) KR20020060163A (de)
AR (1) AR025330A1 (de)
AU (1) AU6440600A (de)
BR (1) BR0013353A (de)
CA (1) CA2376606A1 (de)
CO (1) CO5200840A1 (de)
CZ (1) CZ2002515A3 (de)
DE (1) DE19938825A1 (de)
IL (1) IL147741A0 (de)
MX (1) MXPA02001138A (de)
NO (1) NO20020793D0 (de)
PE (1) PE20010642A1 (de)
PL (1) PL353358A1 (de)
TR (1) TR200200449T2 (de)
UY (1) UY26293A1 (de)
WO (1) WO2001013902A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
AU2002360600B2 (en) 2001-12-11 2007-11-29 University Of Virginia Patent Foundation Use of pramipexole to treat amyotrophic lateral sclerosis
DE10220230A1 (de) * 2002-05-06 2003-11-27 Sanol Arznei Schwarz Gmbh Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms
US20040048779A1 (en) * 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
ES2310258T5 (es) 2002-08-30 2012-05-31 Kyowa Hakko Kogyo Co., Ltd. Antagonistas de los receptores de adenosina A2A para tratar el síndrome de piernas inquietas o mioclono nocturno
DE60204229T2 (de) * 2002-12-02 2006-02-02 Schwarz Pharma Ag Verabreichung von Rotigotine zur Behandlung der Parkinson'schen Krankheit durch Iontophorese
US8518926B2 (en) 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
ES2379117T3 (es) 2006-05-16 2012-04-20 Knopp Neurosciences, Inc. Composiciones de R(+) y S(-) pramipexol y métodos de utilización de las mismas
WO2008009664A2 (en) * 2006-07-19 2008-01-24 Boehringer Ingelheim International Gmbh Treatment of pain
US8524695B2 (en) 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
WO2008113056A2 (en) 2007-03-14 2008-09-18 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
EP1987815A1 (de) * 2007-05-04 2008-11-05 Schwarz Pharma Ag Im Mund-Nasen-Rachenraum verabreichbare pharmazeutische Zusammensetzungen enthaltend Dopaminagonisten zur Vorbeugung und/oder Behandlung von unruhigen Gliedmassen
CN102186350A (zh) 2008-08-19 2011-09-14 诺普神经科学股份有限公司 使用(r)-普拉克索的组合物与方法
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US20150342899A1 (en) * 2012-12-28 2015-12-03 Noven Pharmaceuticals, Inc. Compositions and methods for transdermal delivery of amphetamine and clonidine
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
SMT202100119T1 (it) 2013-07-12 2021-05-07 Knopp Biosciences Llc Trattamento dei livelli elevati di eosinofili e/o basofili
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
EP3038467B1 (de) 2013-08-13 2020-07-29 Knopp Biosciences LLC Zusammensetzungen und verfahren zur behandlung von plasmazellenerkrankungen und prolymphozytischen b-zellen-erkrankungen
AU2014306597B2 (en) 2013-08-13 2018-05-17 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112842A (en) * 1989-11-09 1992-05-12 Boehringer Ingelheim Kg Transdermal administration of 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole
DE4325491A1 (de) * 1993-07-29 1995-02-02 Boehringer Ingelheim Kg Verwendung von zentral wirksamen alpha-2-Agonisten zur Hemmung des Postaggressionsstoffwechsels
DE19701619A1 (de) * 1997-01-17 1998-07-23 Boehringer Ingelheim Pharma Verwendung von Pramipexol zur Behandlung des restless legs syndroms
US6001861A (en) * 1998-01-16 1999-12-14 Pharmacia & Upjohn Company Use of pramipexole in the treatment of restless legs syndrome
WO2000054773A1 (en) * 1999-03-12 2000-09-21 Nitromed, Inc. Dopamine agonists in combination with nitric oxide donors, compositions and methods of use

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112842A (en) * 1989-11-09 1992-05-12 Boehringer Ingelheim Kg Transdermal administration of 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole
DE4325491A1 (de) * 1993-07-29 1995-02-02 Boehringer Ingelheim Kg Verwendung von zentral wirksamen alpha-2-Agonisten zur Hemmung des Postaggressionsstoffwechsels
DE19701619A1 (de) * 1997-01-17 1998-07-23 Boehringer Ingelheim Pharma Verwendung von Pramipexol zur Behandlung des restless legs syndroms
US6001861A (en) * 1998-01-16 1999-12-14 Pharmacia & Upjohn Company Use of pramipexole in the treatment of restless legs syndrome
WO2000054773A1 (en) * 1999-03-12 2000-09-21 Nitromed, Inc. Dopamine agonists in combination with nitric oxide donors, compositions and methods of use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
COLLADO-SEIDEL V. ET AL: "Aetiology and treatment of resless legs syndrome", CNS DRUGS, vol. 12, no. 1, July 1999 (1999-07-01), pages 9 - 20, XP000989833 *
DOOLEY M. ET AL: "Pramipexole. A review of its use in the management of early and advanced parkinson's disease", DRUGS&AGING, vol. 12, no. 6, June 1998 (1998-06-01), pages 495 - 514, XP000989824 *
ZOE A. ET AL: "High dose clonidine in a case of restless legs syndrome", THE ANNALS OF PHARMACOTHERAPY, vol. 28, August 1994 (1994-08-01), pages 878 - 881, XP000989816 *

Also Published As

Publication number Publication date
IL147741A0 (en) 2002-08-14
EP1210081A2 (de) 2002-06-05
BR0013353A (pt) 2002-04-23
CZ2002515A3 (cs) 2002-05-15
PE20010642A1 (es) 2001-06-08
TR200200449T2 (tr) 2002-08-21
KR20020060163A (ko) 2002-07-16
CO5200840A1 (es) 2002-09-27
AR025330A1 (es) 2002-11-20
JP2003507420A (ja) 2003-02-25
CA2376606A1 (en) 2001-03-01
AU6440600A (en) 2001-03-19
NO20020793L (no) 2002-02-18
PL353358A1 (en) 2003-11-17
UY26293A1 (es) 2001-04-30
MXPA02001138A (es) 2002-10-31
NO20020793D0 (no) 2002-02-18
US20020010201A1 (en) 2002-01-24
WO2001013902A2 (de) 2001-03-01
DE19938825A1 (de) 2001-04-26

Similar Documents

Publication Publication Date Title
WO2001013902A3 (de) Wirkstoffkombination enthaltend Clonidin und Pramipexol
WO2001066564A3 (en) Gamma-secretase inhibitors
WO2002003911A8 (en) Prevention and treatment of alzheimer's disease
WO2000058293A3 (en) Glucokinase activators
ZA200006042B (en) Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections.
ZA200200591B (en) Skin care composition.
WO2002064210A3 (en) Combination therapy comprising anti-diabetic and anticonvulsant agents
SE9903759D0 (sv) Pharmaceutically active compounds
WO2002036123A3 (en) New treatments for restless legs syndrome
MY126897A (en) Anticonvulsant derivatives useful for preventing the development of type ii diabetes mellitus and syndrome x
AU5722800A (en) Imidazoline derivatives for the treatment of diabetes, especially type ii diabetes
ATE294799T1 (de) Hydrochloride kondensierter heterozyklen
MX9605023A (es) Compuestos substituidos de imidazolidin-2,4-diona como substancias farmaceuticamente activas.
WO2000058297A3 (en) PROCESS FOR THE PREPARATION OF α-METHYLENE LACTONES
WO2002039954A3 (en) Novel compounds
HK1046631A1 (zh) 含有酮替芬的眼药组合物
IL120443A0 (en) Heterocyclic compounds for the treatment of pancreatitis
NZ336804A (en) Use of pramipexole in the treatment of restless legs syndrome
IL143299A0 (en) Pharmaceutical composition comprising 5-[[4- [3-methyl-4-oxo-3, 4-dihydro-2-quinazolinyl] methoxy] phenyl-methyl] thiadiazolidine-2, 4-dione and the process for its preparation
MXPA03001550A (es) Proceso catalitico para la preparacion de derivados de tiazol.
ZA200005575B (en) Preparation of an aqueous composition for treating leather.
WO2001010422A3 (en) Use of hepoxilins or hepoxilin analogs as antidiabetics, antiinframmatory agents
WO2001052869A3 (de) Präparat und verfahren zur behandlung von sclerotinia-infektionen
WO2001039741A3 (de) Mitomycin c-lösung
EP0911031A3 (de) Verwendung von Arsen zur Herstellung eines Arzneimittels zur Behandlung vom prämenstruellen Syndrom

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AU BG BR CA CN CZ EE HR HU ID IL IN JP KR LT LV MX NO NZ PL RO SG SI SK TR UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2376606

Country of ref document: CA

Ref document number: 2376606

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2002/00007/MU

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 147741

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2000951485

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/001138

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2000 106382

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 008115745

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: PV2002-515

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: P20020144A

Country of ref document: HR

Ref document number: P-103/02

Country of ref document: YU

WWE Wipo information: entry into national phase

Ref document number: 2002/00449

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 1020027002149

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 200200204

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 64406/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 517717

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 3912002

Country of ref document: SK

ENP Entry into the national phase

Ref document number: 20020181

Country of ref document: UZ

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 200200995

Country of ref document: ZA

WWP Wipo information: published in national office

Ref document number: PV2002-515

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 2000951485

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020027002149

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 2000951485

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV2002-515

Country of ref document: CZ